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Abstract: Objectives: We evaluated the comparative performance of different assays used in a
Diagnostic Laboratory Hub that linked 13 HIV health care facilities for the diagnosis of
tuberculosis, histoplasmosis, and cryptococcosis, and describing its functions in
Guatemala compared with other National Reference Laboratories.
 
Methods: The following diagnostic techniques were analyzed in 24 months (2017-
2018) in a cohort of patients with HIV: smear microscopy, mycobacterial and fungal
cultures, isolator blood culture, PCR assays, and antigen detection tests.
 
Results: A total of 4,245 patients were included, 716 (16.2%) had an opportunistic
infection: 249 (34.7%) tuberculosis (TB), 40 (5.6%) NTM, 227 (31.7%) histoplasmosis,
138 (19.3%) cryptococcosis, and 62 (8.6%) had multiple OIs. Two hundred sixty-three
(92.6%; 95%CI, 89-95.1) of TB cases were diagnosed by PCR. Urine antigen assay
detected 94% (95%CI, 89-96) of the disseminated histoplasmosis cases. A lateral flow
assay to detect cryptococcal antigen (CrAg) diagnosed 97% (95%CI, 93.3%-98.7%) of
the cryptococcal cases. In 85 patients (51.5%) with a CSF sample, cryptococcal
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meningitis was diagnosed in 55 (64.7%), of which 18 (32.7%) were only detected by
CrAg.
 
Conclusions: Validated commercial antigen tests, as used in this program, should be
the new gold standard for histoplasmosis and cryptococcosis diagnosis. In their
absence, 35% of disseminated histoplasmosis and 32.7% of cryptococcal meningitis
cases would have been missed. Patients with multiple OIs were frequently diagnosed
and strategies should be designed to screen patients irrespective of their clinical
presentation in low resource settings, Diagnostic Laboratory Hubs can deliver quality
diagnostics services in record time at affordable prices.
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Table 1. Baseline characteristics of the patients with OIs screening 
 
Characteristics 
OIs cases Non-OI cases Total 
n=716 (16.8%) n=3529 (83.2%) n=4245 (100%) 
Gender n % n % n % 
   Male 476 66.5 2201 62.4 2677 63.1 
   Female 235 32.8 1291 36.6 1526 35.9 
   Transsexual 5 0.7 37 1.0 42 1.0 
Age, mean (range)       
   n 709 99.0 3517 99.6 4226 99.5 
   Mean (range) 38 (14-78) 36 (13-89) 36 (13-89)  
Sexual orientation       
   Heterosexual 592 82.7 2642 74.9 3234 76.2 
   Homosexual 68 9.5 602 17.1 670 15.8 
   Bisexual 30 4.2 207 5.9 237 5.6 
   Unknown 26 3.6 78 2.2 104 2.4 
Category of patient             
   Newly HIV infection 385 53.8 1742 49.4 2127 50.1 
   On ARV 191 26.7 1134 32.1 1325 31.2 
   Return/restart 138 19.3 641 18.2 779 18.4 
   Unknown 2 0.3 12 0.3 14 0.3 
CD4 cell count        
   n 477 66.6 2537 71.9 3014 71.0 
   <200 376 78.8 1104 43.5 1480 34.8 
Viral Load        
   n 470 65.6 2355 67.1 2825 66.5 




















Diagnostic modality No. (%) +ve (95% IC) No. (%) +ve (95% IC) No. (%) +ve (95% IC) 
Single test          
  Smear 284 (97.9) 40 14.1 (10.5-18.6) --- --- --- --- --- --- 
  Culture1 286 (98.6) 109 38.1 (32.7-43.9) 211 (77.8) 18 8.5 (5.4-13.0) 85 (51.5) 37 --- 
  Isolator2 207 (71.4) 18 8.7 (5.6-13.3) 190 (70.1) 69 36.3 (29.8-43.3) 129 (75.8) 19 14.7 (9.6-21.8) 
  PCR 284 (97.9) 263 92.6 (89-95.1) 215 (79.3) 135 62.7 (56.6-69.4) --- --- --- 
  Urine Ag --- --- --- 260 (95.9) 188 72.3 (66.5-77.3) --- --- --- 
  Serum Ag --- --- --- --- --- --- 165 (97.0) 165 100 (99.7-100) 
  CSF Ag  --- --- --- --- --- --- 93 (54.7) 64 68.8 (58.8-77.3) 
Combined test           
  Smear + culture 284 (97.9) 119 41.9 (36.3-47.7) --- --- --- --- --- --- 
  Smear + PCR 278 (95.8) 261 93.9 (90.4-96.1) --- --- --- --- --- --- 
  PCR + culture 280 (96.5) 280 100 (98.5-100) 207 (76.4) 138 66.7 (60-72.7) --- --- --- 
  PCR + isolator --- --- --- 157 (57.6) 119 75.8 (68.5-81.8) --- --- --- 
  Urine Ag + isolator --- --- --- 186 (68.6) 136 73.1 (66.3-79.0) --- --- --- 
  Urine Ag + PCR --- --- --- 206 (76.0) 198 96.1 (92.5-98.0) --- --- --- 
  Urine Ag + isolator PCR + Culture --- --- --- 153 (56.4) 153 100 (99.7-100) --- --- --- 
*NMT were excluded because the unique diagnostic technique employed was culture 1Culture was performed from sputum for histoplasmosis and tuberculosis, and 
CSF for cryptococcal meningitis; 2Isolator blood culture 
 
 
Table 3. Main activities of the National Reference Centers and the Diagnostic Laboratory Hub (DLH) in Guatemala 
 National Reference Laboratories  






Centers for Disease 
Control and Prevention 
(CDC) 
United States of America 
National Administration of 
Laboratories and Institutes 










 Detect infectious 
organisms, food-





 Monitor the health of 
communities 
 Invent new ways to 
rapidly test for 
infectious disease in 
the field 
 Arm state, county, 
and local public 
health laboratories 
with the expertise and 
data they need to 
protect their citizens 
 
 Coordinates the 




 Perform diagnostic 
confirmation  
 Contributes to 
surveillance activities 
 Provides scientific 
advice  




 Provides scientific 
advice to the 
Ministry of Health 
and other 
institutions 






agreements, for the 
development of 
health knowledge 
 Provide services 
such as the Central 
Laboratory of 
Public Health 
 Provides technical 
advice  




 Technically support 
research of interest 
for public health and 
epidemiological 
surveillance. 
 Provides support in 
the quality processes 
of the laboratory 
network. 
 Provides high quality 
diagnosis services for 
fungal infections and 
tuberculosis for a 
network of HCFs  
 Coordinates 
communication 
activities for the 
network 
 Implements and 
monitor the delivery of 
specimens between the 
HCF and the DLH 
 Develops informatic 
tools to strengthening 









 Deploy diagnostic 
tests and tools, such 
as advanced 
molecular detection 
technology that helps 
scientists detect 
health threats more 
quickly 
 Description of possible 
warnings to detect 
outbreaks and 
communication to the 






 Participates in 
research in health 
surveillance and 




Training   Sponsors and hosts 
new initiatives and 





 Provides educational 
programs 




 Participates in the 
training activities for 
medical and 
laboratory personnel 





 Supports training 
activities within the 
network 
Centers for Disease Control and Prevention: https://www.cdc.gov/labs/protecting-america.html 
National Administration of Laboratories and Institutes of Health (ANLIS) Dr. G. Malbran, Argentina: http://www.anlis.gov.ar/mision-vision-y-objetivos/ 
Institute Gorgas Reference Central Laboratory: http://www.gorgas.gob.pa/objetivos/  
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Abstract 
Objectives: We evaluated the comparative performance of different assays used in a 
Diagnostic Laboratory Hub that linked 13 HIV health care facilities for the diagnosis of 
tuberculosis, histoplasmosis, and cryptococcosis, and describing its functions in 
Guatemala compared with other National Reference Laboratories.  
 
Methods: The following diagnostic techniques were analyzed in 24 months (2017-2018) in 
a cohort of patients with HIV: smear microscopy, mycobacterial and fungal cultures, 
isolator blood culture, PCR assays, and antigen detection tests.  
 
Results: A total of 4,245 patients were included, 716 (16.2%) had an opportunistic 
infection: 249 (34.7%) tuberculosis (TB), 40 (5.6%) NTM, 227 (31.7%) histoplasmosis, 138 
(19.3%) cryptococcosis, and 62 (8.6%) had multiple OIs. Two hundred sixty-three (92.6%; 
95%CI, 89-95.1) of TB cases were diagnosed by PCR. Urine antigen assay detected 94% 
(95%CI, 89-96) of the disseminated histoplasmosis cases. A lateral flow assay to detect 
cryptococcal antigen (CrAg) diagnosed 97% (95%CI, 93.3%-98.7%) of the cryptococcal 
cases. In 85 patients (51.5%) with a CSF sample, cryptococcal meningitis was diagnosed 
in 55 (64.7%), of which 18 (32.7%) were only detected by CrAg.  
 
Conclusions: Validated commercial antigen tests, as used in this program, should be the 
new gold standard for histoplasmosis and cryptococcosis diagnosis. In their absence, 35% 
of disseminated histoplasmosis and 32.7% of cryptococcal meningitis cases would have 
been missed. Patients with multiple OIs were frequently diagnosed and strategies should 
be designed to screen patients irrespective of their clinical presentation. In low resource 
settings, Diagnostic Laboratory Hubs can deliver quality diagnostics services in record 
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Objectives: We evaluated the comparative performance of different assays used in a 28 
Diagnostic Laboratory Hub that linked 13 HIV health care facilities for the diagnosis of 29 
tuberculosis, histoplasmosis, and cryptococcosis, and describing its functions in 30 
Guatemala compared with other National Reference Laboratories.  31 
 32 
Methods: The following diagnostic techniques were analyzed in 24 months (2017-2018) in 33 
a cohort of patients with HIV: smear microscopy, mycobacterial and fungal cultures, 34 
isolator blood culture, PCR assays, and antigen detection tests.  35 
 36 
Results: A total of 4,245 patients were included, 716 (16.2%) had an opportunistic 37 
infection: 249 (34.7%) tuberculosis (TB), 40 (5.6%) NTM, 227 (31.7%) histoplasmosis, 138 38 
(19.3%) cryptococcosis, and 62 (8.6%) had multiple OIs. Two hundred sixty-three (92.6%; 39 
95%CI, 89-95.1) of TB cases were diagnosed by PCR. Urine antigen assay detected 94% 40 
(95%CI, 89-96) of the disseminated histoplasmosis cases. A lateral flow assay to detect 41 
cryptococcal antigen (CrAg) diagnosed 97% (95%CI, 93.3%-98.7%) of the cryptococcal 42 
cases. In 85 patients (51.5%) with a CSF sample, cryptococcal meningitis was diagnosed 43 
in 55 (64.7%), of which 18 (32.7%) were only detected by CrAg.  44 
 45 
Conclusions: Validated commercial antigen tests, as used in this program, should be the 46 
new gold standard for histoplasmosis and cryptococcosis diagnosis. In their absence, 35% 47 
of disseminated histoplasmosis and 32.7% of cryptococcal meningitis cases would have 48 
been missed. Patients with multiple OIs were frequently diagnosed and strategies should 49 
be designed to screen patients irrespective of their clinical presentation. In low resource 50 
settings, Diagnostic Laboratory Hubs can deliver quality diagnostics services in record 51 




In 2017, the World Health Organization (WHO) published their first guidelines for 54 
managing advanced HIV disease and rapid initiation of antiretroviral therapy, which were 55 
aimed to reduce global HIV morbidity and mortality [1]. These guidelines recommend a 56 
package of interventions to diagnose and treat major opportunistic infections (OIs), which 57 
continue to be an important cause of AIDS-related mortality [1,2]. Hence, identifying 58 
people who are eligible for elements of the package of care, requires quality diagnostic 59 
services which have a crucial role to improve clinical outcomes [3-5].  60 
According to UNAIDS, Guatemala has the largest number of people living with HIV 61 
(PLWH) in Central America, the highest proportion presenting with advanced HIV disease 62 
and high viral loads which are factors that increase the risk of OIs [6,7]. Despite the 63 
development of the HIV health care program and increasing coverage of antiretroviral 64 
therapy (ART), access to accurate testing for OIs was limited. In 2017, to provide 65 
diagnostic services for mycobacterial and fungal infections, a Diagnostic Laboratory Hub 66 
(DLH) was implemented linked with a national network of HIV health care facilities (HCFs). 67 
Here, we evaluate the comparative performance of different diagnostic assays employed 68 
in the DLH and describe the functions of this Health System in comparison with those 69 
provided by National Reference Laboratories (NRL).  70 
 71 
Materials and Methods 72 
Setting and population 73 
From January 2017 through December 2018, diagnostic services for tuberculosis (TB), 74 
non-tuberculous mycobacteria (NTM), histoplasmosis and cryptococcosis were provided 75 
by the DLH to a national network of 13 HIV healthcare facilities (HCFs). Screening for 76 
these OIs was performed regardless of CD4 cell count for (i) newly diagnosed patients; (ii) 77 
patients who had abandoned ART (>90 days) and returned to care, and (iii) those on ART 78 
 
 
when an OI was suspected. Clinical specimens were obtained in the HCFs and delivered 79 
to the DLH by means of a courier service. Additionally, an electronic system was set up to 80 
capture patient data, request diagnostic services and report results.  81 
Laboratory procedures 82 
HCFs were requested to send sputum samples, urine, serum, and 10 ml of blood in an 83 
Isolator® tube (Wampole Laboratories, Cranbury, N.J.). Additional clinical samples were 84 
also received depending on the clinical criteria. Diagnostic methods included: (i) smear for 85 
mycobacteria; (ii) Cultures for fungi and mycobacteria; (iii) Isolator blood culture; (iv) in-86 
house PCR for the detection of M. tuberculosis and H. capsulatum; (v) enzyme-linked 87 
immunosorbent assay (IMMY, Norman, OK, USA) to detect Histoplasma antigen in urine 88 
and; (vi) lateral flow assay (IMMY, Norman, OK, USA) to detect cryptococcal antigen 89 
(CrAg). Detailed methods are described in the supplementary material. 90 
Role of the national reference laboratories (NRLs) and the DLH  91 
To compare the role and functions of the NRLs with the DLH, the official websites of the 92 
Center for Disease Control and Prevention (CDC, USA), the National Administrations of 93 
Laboratories and Health Institutes “Dr. Carlos G. Malbrán” (Argentina), Institute Gorgas 94 
Reference Central Laboratory (Panama), and the National Reference Laboratory 95 
(Guatemala) were searched. 96 
Data analysis  97 
The percentage of the diagnostic performance of each technique, with their corresponding 98 
95% confidence intervals, was calculated against the number of total cases diagnosed. 99 
Chi-squared test was used to compare the positive proportions and significance was set at 100 
P= 0.05.  101 
Geographic Information System (GIS) and google maps tools were used to describe the 102 
location of the DLH and HCFs. Statistical analysis was performed using SPSS 19.0. 103 





Health care network 107 
Guatemala has an area of 108,889 km2, with an asphalted road system of 7,342 Km. The 108 
national network included 13 (81.2%) of the 16 available HCFs in the country, which are 109 
mainly located in rural areas (12 out of 13; 92.3%). Nine (69.3%) of these facilities are 110 
located within an average time of 5 hours to the DLH. Regarding the distribution, 5 (38.5%) 111 
HCFs are located in the west, 4 (30.7%) in the east, 2 (15.3%) in the north, 1 (7.6%) in 112 
south, and 1 (7.6%) in the metropolitan area.   113 
Patients characteristic and OIs diagnosed  114 
During 2017 and 2018, a total of 4,245 PLWH were screened for OIs. Baseline 115 
characteristics are shown in Table 1. A total of 2,677 (63.1%) patients were male with a 116 
mean age of 36 years (range 13-89), and 2,127 (50.1%) patients were newly diagnosed 117 
with HIV infection. Patients with OIs were slightly older than without OIs (38 vs 36 years, P 118 
= 0.002), and had a significantly higher HIV viral load (median Log10 5.1 vs 4.6 copies/mL, 119 
P < 0.0001). Only 71% of patients had CD4 counts done (Table 1).  120 
Seven hundred sixteen (16.9%) patients had OIs: 249 (34.7%) TB, 40 (5.6%) NTM, 227 121 
(31.7%) histoplasmosis, 138 (19.3%) cryptococcosis and 62 (8.6%) had multiple OIs. 122 
Among patients with multiple OIs, there were 24 (38.7%) histoplasmosis plus TB, 15 123 
(24.1%) cryptococcosis plus histoplasmosis, 11 (17.7%) cryptococcosis plus TB, 3 (4.8%) 124 
cryptococcosis plus NTM, 3 (4.8%) TB plus NTM, 3 (4.8%) histoplasmosis plus NTM, and 125 
3 (4.8%) triple infections. Almost 79% of OIs patients had < 200 CD4/mm3 defined as 126 
advanced HIV disease by the WHO (Table 1) [1]. 127 
Comparative diagnostic performance among techniques 128 
Full screening for mycobacteria, histoplasmosis and cryptococcosis was performed in 129 
3,448 (81.2%) patients. Partial screening was done in 797 (18.8%) patients; of those 626 130 
 
 
(78.5%) were tested for histoplasmosis, 371 (46.5%) for cryptococcosis and 272 (34.1%) 131 
for mycobacteria. The diagnostic performance results were similar between those with full 132 
and partial screening. Therefore, all cases were included in order to have more statistical 133 
power (Table 2). 134 
A total of 290 cases of TB, 50 of NTM, 271 of histoplasmosis and 170 of cryptococcosis 135 
were diagnosed. These numbers encompass single infections and cases with multiple OIs; 136 
thus, total cases were used to assess the comparative performance of the diagnostic 137 
techniques (Table 2). 138 
Out of the cases tested for TB (Table 2), direct microscopy was positive in 14.1% (95%CI, 139 
10.5-18.6), culture in 38.1% (95%CI, 32.7-43.9), Isolator blood culture in 8.7% (95%CI, 5.6-140 
13.3) and PCR in 92.6% (95%CI, 89.0-95.1). One hundred and sixty-one (55.5%) were only 141 
detected by PCR. All TB cases were diagnosed by a combination of PCR plus conventional 142 
culture. NTM cases were diagnosed by culture.  143 
Of those tested for histoplasmosis (Table 2), Isolator blood culture, a longstanding high 144 
volume blood culture technique employed before the appearance of urine antigen for 145 
histoplasmosis, was positive in 36.3% (95%CI, 29.8-43.3), urine antigen in 72.3% (95%CI, 146 
66.5-77.3), culture of respiratory samples in 8.5% (95%CI, 5.4-13.0) and PCR in 62.7% 147 
(95%CI, 56.6-69.4), sputum was the sample used for PCR in 92.6% of the samples tested. 148 
Urine antigen and PCR were the only positive test in 95 (35.1%) and 64 (23.6%) cases, 149 
respectively. Combining urine antigen and PCR assay the positive rate increased by 23.8% 150 
(72.3 % to 96.1%).  The median CD4 cell count of those diagnosed by urine antigen testing 151 
or isolator was 33 and 20 cells/mm3 respectively (P=0.667).  152 
For cryptococcal disease, 165 out of 170 cases were diagnosed by serum CrAg. The 153 
remaining 5 cases were diagnosed by CSF CrAg (2 cases) and Isolator blood culture (3 154 
cases). A lumbar puncture was done to 85 (51.5%) of 165 CrAg serum positive patients. A 155 
total of 55 (64.7%) cases had cryptococcal meningitis. Out of these cases, 37 (67.3%) were 156 
 
 
CrAg and culture positive, and 18 (32.7%) were only CrAg positive. Of those, 35 and 16 157 
cases had CD4 cell counts, with a median of 36 and 47 cells/mm3, respectively (P=0.692).  158 
 159 
Functions of the NRLs and the DLH 160 
A review of the main activities of NRL are summarized in Table 3. The functions listed are 161 
consistent with the role of assessment, policy development, and assurance, which 162 
contribute to the public health system. Main activities included: confirmatory/reference 163 
diagnostic testing, typing of microorganisms, assessment of antibiotic resistance, and 164 
standardization of methodologies. In Guatemala, the NRL perform most of these activities; 165 
however, do not include a Reference Laboratory for fungal infections. For the DLH the 166 
main role is to provide rapid diagnostic services and to coordinate activities to improve the 167 
management of OIs in the network. Indirectly, the DLH collects epidemiological data as a 168 
result of the diagnostic activities. This information is shared with the HCF network as well 169 
as with the Ministry of Health.  170 
 171 
Discussion 172 
Access to accurate diagnosis services is crucial to guide therapy and to improve clinical 173 
outcomes. In this study a DLH provided rapid diagnostic services for OIs to a national 174 
network of HCFs. We used a courier service for specimen transportation and a similar 175 
strategy implemented in Uganda showed an eightfold increase in referral samples and TB 176 
case detection [10]. In Guatemala, this system was able to provide diagnostic access to 177 
81.2% of the HCFs in the country including the most remote ones.  178 
Regarding TB, a low positivity rate (14.1%) of smears was found. Lower performance of 179 
sputum microscopy in HIV patients has been widely described because they frequently 180 
have paucibacillary infections [11]. However, our results were lower than those found by 181 
previous studies, where sensitivity ranged from 30-48% [11,12]. A low positivity rate was 182 
 
 
also found for TB culture with 38.1% vs 62.6% in the literature [13]. Nevertheless, culture 183 
is essential to isolate the microorganism, and determine drug susceptibility, and monitor 184 
resistance rates. To increase the detection rate, it would be necessary to explore the use 185 
of different transportation systems that could improve mycobacteria recovery. TB PCR 186 
detected 92.6% of the cases, which is similar to other reports (90 to 100%) [14,15]. Xpert 187 
MTB/RIF and lateral flow lipoarabinomannan (LAM) assay were not available at the DLH. 188 
Concerning histoplasmosis, the sensitivity of the urine antigen (72.3%) and the isolator 189 
blood culture (36.3%) were lower than previously reported 81-98% and 66.7-74.2% 190 
respectively [16,19]. It is well-known that urine antigen is designed to diagnose 191 
disseminated histoplasmosis and thus, it is expected to be negative in localized 192 
histoplasmosis. Unfortunately, in this study clinical symptoms and signs that could have 193 
helped to classify the histoplasmosis cases were not recorded by the DLH. Therefore, we 194 
assumed that a patient with a positive urine antigen, and/or Isolator blood culture had 195 
disseminated histoplasmosis. Considering this definition, the number of disseminated 196 
histoplasmosis was 205 (77.3%) out of 265 patients. Of those, 94% had a urine antigen 197 
positive. In patients with Isolator and urine antigen test, seven cases had a positive 198 
Isolator blood culture and negative result in urine antigen, which means that the use of 199 
both techniques increases the positivity rate by 3.5% but at a substantially higher cost. The 200 
cost of one determination of Histoplasma antigen in Guatemala is $13 vs $ 22 for the 201 
Isolator blood culture. Other study found that histoplasmosis may cause proteinuria [20] 202 
and other kidney damage, that in some cases, could render a false negative antigen result. 203 
An assay designed for TB in urine samples, LAM have shown that early morning urine and 204 
sample concentration can increase the sensitivity [21]. Further studies are needed to 205 
evaluate the influence of these factors. The urine antigen test has resulted in a higher 206 
detection of the histoplasmosis cases. Global access to these diagnostic tests, especially 207 
 
 
in Latin America, would increase awareness as well as the availability of an early 208 
diagnosis and treatment which will certainly increase the patient survival.  209 
For cryptococcosis, we found that the positivity rate of the CrAg test in serum was 210 
consistent with previous reports (98-100%) [22,23]. Eighteen meningitis cases were 211 
diagnosed only by CrAg detection, highlighting the importance of this assay in the rapid 212 
diagnosis of this severe infection. CSF culture alone would have only diagnosed 67% of 213 
cryptococcal meningitis cases and at a slower response rate. Similar results were reported 214 
in other study with 10% of patients with a positive CSF CrAg having a negative culture 215 
[24]. The DLH used CrAg CSF results as India ink microscopy is less sensitive and time 216 
consuming [25]. 217 
Taking into account our findings, we recommend the following approaches. (i) The sensitivity 218 
of direct microscopy for AFB is very low. It is a demanding technique that requires patience 219 
and expertise to get good results but provides a quick answer. Laboratories should evaluate 220 
the usefulness of this technique considering their available workforce. (ii) Culture is an 221 
insensitive technique for both, Mycobacteria and fungi, but in our opinion, should be 222 
maintained in order to recover the microorganisms for proper identification, susceptibility 223 
testing, and typing. (iii) Isolator blood culture has a low sensitivity and we do not recommend 224 
its use as a diagnostic tool. However, it could be useful for the recovery of Histoplasma 225 
isolates when the urine antigen is positive. Therefore, if a patient had a positive urine 226 
antigen, we would recommend asking for an urgent Isolator blood culture. (iv) TB PCR 227 
should be used because it has a good sensitivity and delivers results in a short time. 228 
However, we recommend the implementation of standardized commercial techniques, 229 
already available, such as the Xpert MTB/RIF assays. For histoplasmosis there is no 230 
commercial PCR system and, although our in-house PCR has an acceptable performance, 231 
we cannot give a clear recommendation about its use until further analysis about its 232 
comparative diagnostic performance in the diagnosis of localized histoplasmosis is done; 233 
 
 
(v) Antigen detection techniques are the current gold standard for diagnosing cryptococcosis 234 
and disseminated histoplasmosis and should be available in every single laboratory dealing 235 
with OIs in PLW. Without these tests, 95 (35%) disseminated histoplasmosis and 18 (32.7%) 236 
cryptococcal meningitis cases would have been missed. Currently, these methods are 237 
included in the WHO Essential Diagnostics List [26]. (vi) The rate of patients with multiple 238 
OIs in advanced HIV in Guatemala is substantial. Therefore, optimal case-finding strategies 239 
should include screening for potential OIs irrespective of their clinical presentation, and the 240 
local prevalence of different OIs. Similar diagnostic interventions should be considered in 241 
other low resource settings. 242 
This study also demonstrates that the DLH does not interfere with other health care 243 
systems. The European Center for Diseases Control (ECDC) classifies the main activities 244 
of microbiology reference laboratories into five core functions: i) diagnostic confirmation 245 
services, which include reference methods for specific pathogens with a low prevalence or 246 
not covered by the usual commercial portfolio; ii) scientific advice; iii) collaboration and 247 
research; iv) provision of reference materials, and v) monitoring alert and response [27]. 248 
The functions of the NRLs are similar to the core activities outlines by the ECDC, which 249 
reflect the homogeneity of the Reference Laboratory activities. Guatemala NRL aims are 250 
similar but OIs diagnosis for PLWH is not included in its activity’s portfolio. On the other 251 
hand, the main goal of the DLH is to provide quick diagnostics services for improving the 252 
care and management of patients as well as to aggregate the epidemiology data obtained 253 
from the diagnostic analysis. Besides, with more automation, the DHL can manage 254 
thousands of samples without a huge increase in labor costs.  255 
This study has several limitations. The transport time was not measured and thus we 256 
cannot determine their impact. Additionally, we did not collect data of patients’ symptoms 257 
and the added value of it was not determined. Despite this, a large number of patients and 258 
events were analyzed allowing us to make clear diagnostic recommendations for other 259 
 
 
countries and states that want to improve the diagnosis of OIs in PLWH. The DLH is a 260 
promising approach to provide diagnostic services to a large community of HCFs at an 261 
affordable cost.  262 
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aids@wolterskluwer.com 
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Subject: Revision and resubmission of manuscript AIDS-D-20-00384 
Dear Dr Franks, 
 
 
Thank you for the opportunity to revise our manuscript. The suggestions offered by the 
reviewers have been helpful. We have included the reviewer comments immediately after 
this letter and responded to them individually. We also provide a point-by-point list of the 
changes as requested.  
In attention to the reviewer’s comments, we have considered remove Figure 1. We 
consider it is useful to show how the network is spread in the country, but the cost is 
prohibitive for us. You have to take into account that project resources are limited, and the 
priorities are the diagnosis and treatment of the patients. If you can consider to 
substantially decrease the costs of the publication, we would be very happy to include the 
figure. Sorry to be so direct but we have strong constraints and although it is mandatory to 
share our findings with the community, specially to prove that with the right resources for 
access to diagnosis and treatment everything is possible, we cannot afford to spend a lot 
of money in the publications. Sure, you fully understand our position.  All the changes are 
listed at the final of the document.   
 




Juan Luis Rodriguez Tudela, MD, PhD 









Reviewer #1: This is an interesting paper on an important initiative in central 
America. 
i think that the discussion stays very focused on the "technical" aspects and should 
take a step back and reflect on the importance of such a model in Latin America, 
and elsewhere, where the burden of histoplasmosis is high for lack of diagnostic 
tests. their intervention is an interesting model that answers the ambitions stated in 
the manaus declaration. 
 
R. Thank you for this observation. Concerning to the Manaus declaration, we have 
added (page 9, line 206-209): “The urine antigen test has resulted in a higher 
detection of the histoplasmosis cases. Global access to these diagnostic tests, 
especially in Latin America, would increase awareness as well as the availability of 
an early diagnosis and treatment which will certainly increase the patient survival”. 
(page 10, line 241-242): “Similar diagnostic interventions should be considered in 
other low resource settings””. 
 
Reviewer #2: This is an interesting paper which reports important data on the 
experience of using newer vs. older diagnostic methods to diagnose opportunistic 
infections (OI) in HIV-infected patients. It is an important paper since it addresses 
the real-world utility of various diagnostic tests in a resource-limited setting. The 
authors should consider addressing the following: 
1. A minor terminology issue: Since all of the patients in this report are, by 
definition, "co-infected" with HIV and one or more OI's, would not call patients with 
multiple simultaneous OI's "co-infected." Suggest just stating that some patients 
had more than one simultaneous OI. 
 
R. We agree with the better use of “multiple OIs” terminology. We have changed it 
through the entire manuscript. Abstract, Page 2 (line 39), Page 2 (line 49). 
Manuscript, Page 5 (line 122), Page 6 (line 136), Page 10 (line 238-239). 
 
2. The authors emphasize that a significant percentage of patients with both 
histoplasmosis and cryptococcosis would not have been detected if only traditional 
diagnostic methods had been used. It would be useful for the authors to either 
describe in the results (possibly prepare a table) showing more details of the 
characteristics of the patients who were diagnosed vs. missed with traditional 
smears/stains/cultures vs. newer diagnostics. For example, of the histo patients- 
breakdown of disseminated vs. pulmonary or other site; CD4+ lymphocyte counts of 
patients by group. Similarly with cryptococosis- Did the patients who had negative 
cultures/India ink have higher CD4+ counts? Were the patients with discrepant 
results ill with meningitis vs. cryptococcemia without meningitis? More details 
 
 
about all the patients with discrepant results would be helpful to both clinicians and 
microbiologists. 
R. We thank the reviewer for this comment and we agree it is an important point, 
however we don’t think that a new table could help in clarifying this point. 
Regarding Cryptococcal meningitis, it is important to mention that in the results 
section we said that all patients with a CSF negative culture but with a positive 
CrAg result had serum CrAg positive results. To compare these groups, we have 
now included (Page 6, line 158-160): “Of those, 35 and 16 cases had CD4 cell 
counts, with a median of 36 and 47 cells/mm3, respectively (P=0.692).” 
Regarding disseminated histoplasmosis, 95 patients who only had a positive 
antigen test were considered as disseminated cases. The remaining cases were 
diagnosed by different test combinations (results section). To clarify and compare 
cases only diagnosed with antigen or isolator we have added (Page 6, line 151-
152): “The median CD4 cell count of those diagnosed by urine antigen testing or 
isolator was 33 and 20 cells/mm3 respectively (P=0.667).”  
In addition, we highlight in the discussion section the importance of these 
commercial antigen tests as the new gold standard for rapid histoplasmosis and 
cryptococcosis diagnosis. As discussed, we were not able to include clinical 
symptoms and signs that could have helped to classify the histoplasmosis cases as 
disseminated or localized  
----------------------------------- 
Point-by-point list of the changes: 
 Adding (page 9, line 206-209): “The urine antigen test has resulted in a higher 
detection of the histoplasmosis cases. Global access to these diagnostic tests, 
especially in Latin America, would increase awareness as well as the availability of 
an early diagnosis and treatment which will certainly increase the patient survival”. 
and (page 10, line 241-242): “Similar diagnostic interventions should be considered 
in other low resource settings””. 
 Use of “multiple OIs” terminology instead of coinfections and structure of the 
sentence: Abstract, Page 2 (line 39), Page 2 (line 49). Manuscript, Page 5 (line 
122), Page 6 (line 136), Page 10 (line 238-239). 
 Adding (Page 6, line 158-160): “Of those, 35 and 16 cases had CD4 cell counts, 
with a median of 36 and 47 cells/mm3, respectively (P=0.692).” 
 Adding (Page 6, line 151-152): “The median CD4 cell count of those diagnosed by 
urine antigen testing or isolator was 33 and 20 cells/mm3 respectively (P=0.667).” 
 Remove Figure 1 (Page 3, line 76) and (Page 5, line 110-111).  
Change the title “Acknowledgement” for “Authors' contributions” Page 11, Line 264 
